225 related articles for article (PubMed ID: 20945165)
1. Mouse ataxin-3 functional knock-out model.
Switonski PM; Fiszer A; Kazmierska K; Kurpisz M; Krzyzosiak WJ; Figiel M
Neuromolecular Med; 2011 Mar; 13(1):54-65. PubMed ID: 20945165
[TBL] [Abstract][Full Text] [Related]
2. A knockin mouse model of spinocerebellar ataxia type 3 exhibits prominent aggregate pathology and aberrant splicing of the disease gene transcript.
Ramani B; Harris GM; Huang R; Seki T; Murphy GG; Costa Mdo C; Fischer S; Saunders TL; Xia G; McEachin RC; Paulson HL
Hum Mol Genet; 2015 Mar; 24(5):1211-24. PubMed ID: 25320121
[TBL] [Abstract][Full Text] [Related]
3. A new humanized ataxin-3 knock-in mouse model combines the genetic features, pathogenesis of neurons and glia and late disease onset of SCA3/MJD.
Switonski PM; Szlachcic WJ; Krzyzosiak WJ; Figiel M
Neurobiol Dis; 2015 Jan; 73():174-88. PubMed ID: 25301414
[TBL] [Abstract][Full Text] [Related]
4. Ataxin-3 protein modification as a treatment strategy for spinocerebellar ataxia type 3: removal of the CAG containing exon.
Evers MM; Tran HD; Zalachoras I; Pepers BA; Meijer OC; den Dunnen JT; van Ommen GJ; Aartsma-Rus A; van Roon-Mom WM
Neurobiol Dis; 2013 Oct; 58():49-56. PubMed ID: 23659897
[TBL] [Abstract][Full Text] [Related]
5. Comparison of spinocerebellar ataxia type 3 mouse models identifies early gain-of-function, cell-autonomous transcriptional changes in oligodendrocytes.
Ramani B; Panwar B; Moore LR; Wang B; Huang R; Guan Y; Paulson HL
Hum Mol Genet; 2017 Sep; 26(17):3362-3374. PubMed ID: 28854700
[TBL] [Abstract][Full Text] [Related]
6. Calpain-mediated ataxin-3 cleavage in the molecular pathogenesis of spinocerebellar ataxia type 3 (SCA3).
Hübener J; Weber JJ; Richter C; Honold L; Weiss A; Murad F; Breuer P; Wüllner U; Bellstedt P; Paquet-Durand F; Takano J; Saido TC; Riess O; Nguyen HP
Hum Mol Genet; 2013 Feb; 22(3):508-18. PubMed ID: 23100324
[TBL] [Abstract][Full Text] [Related]
7. Silencing mutant ATXN3 expression resolves molecular phenotypes in SCA3 transgenic mice.
Rodríguez-Lebrón E; Costa Mdo C; Luna-Cancalon K; Peron TM; Fischer S; Boudreau RL; Davidson BL; Paulson HL
Mol Ther; 2013 Oct; 21(10):1909-18. PubMed ID: 23820820
[TBL] [Abstract][Full Text] [Related]
8. A mutant ataxin-3 fragment results from processing at a site N-terminal to amino acid 190 in brain of Machado-Joseph disease-like transgenic mice.
Colomer Gould VF; Goti D; Pearce D; Gonzalez GA; Gao H; Bermudez de Leon M; Jenkins NA; Copeland NG; Ross CA; Brown DR
Neurobiol Dis; 2007 Sep; 27(3):362-9. PubMed ID: 17632007
[TBL] [Abstract][Full Text] [Related]
9. Blood and cerebellar abundance of ATXN3 splice variants in spinocerebellar ataxia type 3/Machado-Joseph disease.
Raposo M; Hübener-Schmid J; Tagett R; Ferreira AF; Vieira Melo AR; Vasconcelos J; Pires P; Kay T; Garcia-Moreno H; Giunti P; Santana MM; Pereira de Almeida L; Infante J; van de Warrenburg BP; de Vries JJ; Faber J; Klockgether T; Casadei N; Admard J; Schöls L; Riess O; ; Costa MDC; Lima M
Neurobiol Dis; 2024 Apr; 193():106456. PubMed ID: 38423193
[TBL] [Abstract][Full Text] [Related]
10. Mutant ataxin-3 with an abnormally expanded polyglutamine chain disrupts dendritic development and metabotropic glutamate receptor signaling in mouse cerebellar Purkinje cells.
Konno A; Shuvaev AN; Miyake N; Miyake K; Iizuka A; Matsuura S; Huda F; Nakamura K; Yanagi S; Shimada T; Hirai H
Cerebellum; 2014 Feb; 13(1):29-41. PubMed ID: 23955261
[TBL] [Abstract][Full Text] [Related]
11. Inactivation of PNKP by mutant ATXN3 triggers apoptosis by activating the DNA damage-response pathway in SCA3.
Gao R; Liu Y; Silva-Fernandes A; Fang X; Paulucci-Holthauzen A; Chatterjee A; Zhang HL; Matsuura T; Choudhary S; Ashizawa T; Koeppen AH; Maciel P; Hazra TK; Sarkar PS
PLoS Genet; 2015 Jan; 11(1):e1004834. PubMed ID: 25590633
[TBL] [Abstract][Full Text] [Related]
12. Polyglutamine-expanded ataxin-3 impairs long-term depression in Purkinje neurons of SCA3 transgenic mouse by inhibiting HAT and impairing histone acetylation.
Chou AH; Chen YL; Hu SH; Chang YM; Wang HL
Brain Res; 2014 Oct; 1583():220-9. PubMed ID: 25139423
[TBL] [Abstract][Full Text] [Related]
13. [Polyglutamine-expanded ataxin-3 is degraded by autophagy].
Xiao H; Tang J; Hu Z; Tan J; Tang B; Jiang Z
Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2010 Feb; 27(1):23-8. PubMed ID: 20140862
[TBL] [Abstract][Full Text] [Related]
14. The role of the mammalian DNA end-processing enzyme polynucleotide kinase 3'-phosphatase in spinocerebellar ataxia type 3 pathogenesis.
Chatterjee A; Saha S; Chakraborty A; Silva-Fernandes A; Mandal SM; Neves-Carvalho A; Liu Y; Pandita RK; Hegde ML; Hegde PM; Boldogh I; Ashizawa T; Koeppen AH; Pandita TK; Maciel P; Sarkar PS; Hazra TK
PLoS Genet; 2015 Jan; 11(1):e1004749. PubMed ID: 25633985
[TBL] [Abstract][Full Text] [Related]
15. Reversibility of symptoms in a conditional mouse model of spinocerebellar ataxia type 3.
Boy J; Schmidt T; Wolburg H; Mack A; Nuber S; Böttcher M; Schmitt I; Holzmann C; Zimmermann F; Servadio A; Riess O
Hum Mol Genet; 2009 Nov; 18(22):4282-95. PubMed ID: 19666958
[TBL] [Abstract][Full Text] [Related]
16. Silencing mutant ataxin-3 rescues motor deficits and neuropathology in Machado-Joseph disease transgenic mice.
Nóbrega C; Nascimento-Ferreira I; Onofre I; Albuquerque D; Hirai H; Déglon N; de Almeida LP
PLoS One; 2013; 8(1):e52396. PubMed ID: 23349684
[TBL] [Abstract][Full Text] [Related]
17. A Novel SCA3 Knock-in Mouse Model Mimics the Human SCA3 Disease Phenotype Including Neuropathological, Behavioral, and Transcriptional Abnormalities Especially in Oligodendrocytes.
Haas E; Incebacak RD; Hentrich T; Huridou C; Schmidt T; Casadei N; Maringer Y; Bahl C; Zimmermann F; Mills JD; Aronica E; Riess O; Schulze-Hentrich JM; Hübener-Schmid J
Mol Neurobiol; 2022 Jan; 59(1):495-522. PubMed ID: 34716557
[TBL] [Abstract][Full Text] [Related]
18. Polyglutamine-induced neurodegeneration in SCA3 is not mitigated by non-expanded ataxin-3: conclusions from double-transgenic mouse models.
Hübener J; Riess O
Neurobiol Dis; 2010 Apr; 38(1):116-24. PubMed ID: 20079840
[TBL] [Abstract][Full Text] [Related]
19. Nuclear localization of ataxin-3 is required for the manifestation of symptoms in SCA3: in vivo evidence.
Bichelmeier U; Schmidt T; Hübener J; Boy J; Rüttiger L; Häbig K; Poths S; Bonin M; Knipper M; Schmidt WJ; Wilbertz J; Wolburg H; Laccone F; Riess O
J Neurosci; 2007 Jul; 27(28):7418-28. PubMed ID: 17626202
[TBL] [Abstract][Full Text] [Related]
20. Motor uncoordination and neuropathology in a transgenic mouse model of Machado-Joseph disease lacking intranuclear inclusions and ataxin-3 cleavage products.
Silva-Fernandes A; Costa Mdo C; Duarte-Silva S; Oliveira P; Botelho CM; Martins L; Mariz JA; Ferreira T; Ribeiro F; Correia-Neves M; Costa C; Maciel P
Neurobiol Dis; 2010 Oct; 40(1):163-76. PubMed ID: 20510362
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
